Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,894 | 2,038 | 2,073 | 2,142 | 2,289 | 2,490 | 2,487 | 2,575 |
| Operating profit | $m | 416 | 402 | ||||||
| Net profit | $m | 113 | 118 | 63 | 130 | 191 | 179 | 124 | 394 |
| EPS reported | $ | 0.09 | 0.06 | ||||||
| Operating cashflow per share | $ | 0.24 | 0.20 | ||||||
| Capex per share | $ | 0.07 | 0.10 | ||||||
| FCF per share | $ | 0.17 | 0.10 | ||||||
| Free cash flow | $m | 342 | 191 | ||||||
| Net debt | $m | 1,323 | 1,651 | ||||||
| Book value equity | $m | 1,519 | 1,436 | ||||||
| Book value per share | $ | 0.75 | 0.73 | ||||||
| Number of shares | m | 2,034.29 | 1,960.35 | ||||||
| DPS (TTM paid) | $ | 0.07 | 0.08 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 37.23 | - | ||||||
| P/B LTM | x | 4.36 | 4.16 | ||||||
| P/S LTM | x | 2.66 | 2.40 | ||||||
| P/FCF LTM | x | 19.37 | 31.21 | ||||||
| EV/EBITDA LTM | x | 12.52 | 12.16 | ||||||
| EV/Sales LTM | x | 3.24 | 3.06 | ||||||
| Earnings Yield LTM | % | 2.69% | 2.08% | ||||||
| FCF Yield | % | 5.16% | 3.20% | ||||||
| Quality | |||||||||
| ROE | % | 11.77% | 8.40% | ||||||
| ROIC | % | 9.82% | 9.44% | ||||||
| Operating margin | % | 16.69% | 16.16% | ||||||
| Gross margin | % | 55.19% | 55.07% | ||||||
| FCF/Sales | % | 13.74% | 7.69% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -5.48% | -43.27% | ||||||
| Sales Growth YoY | % | +8.78% | +5.58% | ||||||
| Net Income Growth YoY | % | -6.21% | -42.73% | ||||||
| FCF Growth | % | +24.78% | -45.28% | ||||||
| Operating Profit Growth | % | +27.90% | +13.24% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 2.16% | 2.47% | ||||||
| Dividend Growth | % | +8.41% | +12.90% | ||||||
| Payout Ratio | % | 79.94% | 80.00% | ||||||
| FCF/Debt | x | 0.23 | 0.11 | ||||||
| Net Debt/EBITDA | x | 2.24 | 2.63 | ||||||
| EBIT/Net interest | x | 5.81 | 5.34 | ||||||
| Net debt/market cap | % | 19.97% | 27.65% | ||||||
| Net debt/Equity | x | 0.87 | 1.15 | ||||||
| Gross debt/equity | x | 1.00 | 1.22 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free